Skip to main content
UC Davis Children’s Hospital

UC Davis Children’s Hospital

Developmental-Behavioral Pediatric Services

Developmental-behavioral pediatricians have the training and expertise to evaluate and care for children with developmental, learning, and related problems. Working collaboratively with families, they evaluate, counsel, and provide treatment for children and adolescents with a wide range of difficulties, including:

  • Developmental disabilities, such as autism spectrum disorders (ASD),  intellectual disability,  cerebral palsy, spina bifida, genetic disorders and visual and hearing impairments
  • Delayed development in speech, language, motor skills, and thinking ability
  • Attention and behavioral disorders, such as attention-deficit/hyperactivity disorder and such conditions as oppositional-defiant behavior, conduct problems, depression, and anxiety disorders
  • Learning disorders, such as dyslexia, writing difficulties, math disorders, and other school-related learning problems
  • Tics, Tourette syndrome, and other habit disorders
  • Regulatory disorders, such as sleep disorders, feeding problems, and discipline difficulties

By sharing faculty with the renowned UC Davis MIND Institute, a national leader in the prevention, care, and cures of neurodevelopmental disorders, the UC Davis Children’s Hospital is uniquely positioned to provide developmental-behavioral pediatric services.

Among the distinguished members of the UC Davis Children’s Hospital team are:

  • MIND Institute Medical Director Randi J. Hagerman MD, a Distinguished  Professor and Endowed Chair in Fragile X Research who is internationally recognized as a clinician and researcher in the field of fragile X, the most common inherited cause of intellectual disability and autism. She is also an expert in a Parkinson’s disease-like condition called fragile X-associated tremor/ataxia syndrome, or FXTAS, which she and her husband, Paul Hagerman MD PhD, discovered. Her research focuses on targeted treatments for fragile X syndrome, FXTAS, premutation involvement and autism spectrum disorders. These treatments include new therapeutic agents that have the potential to reverse the neurobiological abnormalities of these conditions.
  • Professor of Pediatrics Robin Hansen isthe director of the UC Davis Center for Excellence in Developmental Disabilities, chief of Child Development and Behavioral Pediatrics, and director of Clinical Programs at the MIND Institute. She has vast experience in treating children with neurodevelopmental disorders as well as in clinical research, which has focused on effects of prenatal drug exposure, gene-environment interactions, early identification of ASD, and biomedical treatments for neurodevelopmental disorders.

Joining them on the team are, among others:

  • Assistant Professor Kathleen Angkustsiri MD, a developmental-behavioral pediatrician with interests in neurodevelopmental disorders, including 22q11.2 deletion syndrome, ASD and fragile X syndrome. She is involved in research on congenital malformations in children with ASD and clinical trials for autism and fragile X syndrome.
  • Associate Clinical Professor Lauren Plumer MD, who is interested in genetic and environmental influences on early childhood development. At the MIND Institute, she directs the comprehensive developmental pediatric evaluation program for children placed in foster care and is involved in research regarding the diagnosis of ASD.
  • Associate Clinical Professor Mary Beth Steinfeld MD, whose clinical and research interests include typical and atypical child development, infant mental health, feeding disorders, and diagnosis and management of ASD and other developmental disorders.